Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more
Teva Pharmaceutical Industries Limited (TEVJF) - Total Assets
Latest total assets as of December 2025: $40.76 Billion USD
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEVJF) holds total assets worth $40.76 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Teva Pharmaceutical Industries Limited - Total Assets Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Teva Pharmaceutical Industries Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Teva Pharmaceutical Industries Limited's total assets of $40.76 Billion consist of 34.2% current assets and 65.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.7% |
| Accounts Receivable | $3.71 Billion | 9.1% |
| Inventory | $3.18 Billion | 7.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.78 Billion | 9.3% |
| Goodwill | $16.00 Billion | 39.3% |
Asset Composition Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Teva Pharmaceutical Industries Limited's current assets represent 34.2% of total assets in 2025, a decrease from 61.8% in 1985.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, down from 16.1% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 39.3% of total assets.
Teva Pharmaceutical Industries Limited Competitors by Total Assets
Key competitors of Teva Pharmaceutical Industries Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Teva Pharmaceutical Industries Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Teva Pharmaceutical Industries Limited generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Teva Pharmaceutical Industries Limited generates $ 3.75 in net profit.
Teva Pharmaceutical Industries Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.04 | 0.98 | 1.03 |
| Quick Ratio | 0.80 | 0.75 | 0.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $490.10 Million | $ -244.00 Million | $ 312.00 Million |
Teva Pharmaceutical Industries Limited - Advanced Valuation Insights
This section examines the relationship between Teva Pharmaceutical Industries Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.18 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | $40.76 Billion |
| Market Capitalization | $15.79 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Teva Pharmaceutical Industries Limited's assets below their book value (0.39 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Teva Pharmaceutical Industries Limited's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Teva Pharmaceutical Industries Limited (1985–2025)
The table below shows the annual total assets of Teva Pharmaceutical Industries Limited from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $40.76 Billion | +3.64% |
| 2024-12-31 | $39.33 Billion | -9.55% |
| 2023-12-31 | $43.48 Billion | -1.20% |
| 2022-12-31 | $44.01 Billion | -7.68% |
| 2021-12-31 | $47.67 Billion | -5.87% |
| 2020-12-31 | $50.64 Billion | -11.88% |
| 2019-12-31 | $57.47 Billion | -5.29% |
| 2018-12-31 | $60.68 Billion | -14.07% |
| 2017-12-31 | $70.61 Billion | -23.98% |
| 2016-12-31 | $92.89 Billion | +71.20% |
| 2015-12-31 | $54.26 Billion | +16.88% |
| 2014-12-31 | $46.42 Billion | -2.29% |
| 2013-12-31 | $47.51 Billion | -6.13% |
| 2012-12-31 | $50.61 Billion | +0.93% |
| 2011-12-31 | $50.14 Billion | +28.40% |
| 2010-12-31 | $39.05 Billion | +15.50% |
| 2009-12-31 | $33.81 Billion | +2.75% |
| 2008-12-31 | $32.90 Billion | +40.54% |
| 2007-12-31 | $23.41 Billion | +14.37% |
| 2006-12-31 | $20.47 Billion | +97.08% |
| 2005-12-31 | $10.39 Billion | +7.84% |
| 2004-12-31 | $9.63 Billion | +62.82% |
| 2003-12-31 | $5.92 Billion | +27.86% |
| 2002-12-31 | $4.63 Billion | +33.72% |
| 2001-12-31 | $3.46 Billion | +21.17% |
| 2000-12-31 | $2.86 Billion | +66.60% |
| 1999-12-31 | $1.71 Billion | +19.36% |
| 1998-12-31 | $1.44 Billion | +20.83% |
| 1997-12-31 | $1.19 Billion | -4.27% |
| 1996-12-31 | $1.24 Billion | +42.48% |
| 1995-12-31 | $871.30 Million | +28.89% |
| 1994-12-31 | $676.00 Million | +20.09% |
| 1993-12-31 | $562.90 Million | +26.49% |
| 1992-12-31 | $445.00 Million | +18.13% |
| 1991-12-31 | $376.70 Million | +9.57% |
| 1990-12-31 | $343.80 Million | +19.92% |
| 1989-12-31 | $286.70 Million | +15.56% |
| 1988-12-31 | $248.10 Million | +73.74% |
| 1986-12-31 | $142.80 Million | +2.66% |
| 1985-12-31 | $139.10 Million | -- |